UGT1A1 and neutropenia: Consistently, another metanalysis of Caucasian patients with metastatic colo-rectal cancer who received irinotecan found a 2-to-4-time increased risk of severe neutropenia and diarrhea in UGT1A1*1 6/6 carriers as compared with UGT1A1*28 7/7 carriers.